Vaso Corporation (VASO)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vaso Corporation (VASO) with AI Score 49/100 (Weak). Vaso Corporation operates in the healthcare equipment and IT sectors, offering a range of products and services including diagnostic imaging solutions, medical devices, and IT support. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026Vaso Corporation (VASO) Healthcare & Pipeline Overview
Vaso Corporation provides healthcare IT solutions, medical devices, and professional sales services, primarily focusing on diagnostic imaging and therapeutic systems. With a market capitalization of $0.03 billion, the company operates through IT, Professional Sales Service, and Equipment segments, serving healthcare providers both domestically and internationally.
Investment Thesis
Vaso Corporation presents a mixed investment profile. The company's gross margin of 60.9% and ROE of 9.6% indicate efficient operations and profitability. Its low beta of 0.49 suggests lower volatility compared to the broader market. A profit margin of 2.9% demonstrates the ability to convert revenue into profit. Growth catalysts include expansion of the IT segment and increased sales of proprietary medical devices. However, the high debt-to-equity ratio of 7.19 and the absence of a dividend may deter some investors. The company's reliance on GEHC for equipment sales also poses a risk. The market capitalization of $0.03 billion reflects its small size and potential for growth, but also exposes it to risks associated with smaller companies.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross margin of 60.9% indicates strong pricing power and efficient cost management.
- Return on Equity (ROE) of 9.6% demonstrates the company's ability to generate profit from shareholders' investments.
- Debt-to-Equity ratio of 7.19 suggests a highly leveraged financial structure, which could pose risks.
- Profit margin of 2.9% shows the percentage of revenue that turns into profit.
- Market capitalization of $0.03 billion reflects its small size and growth potential.
Competitors & Peers
Strengths
- Diverse product and service offerings across IT, sales, and equipment segments.
- Established partnership with GE Healthcare.
- Proprietary medical device technology.
- Recurring revenue from IT service contracts.
Weaknesses
- Small market capitalization limits access to capital.
- High debt-to-equity ratio increases financial risk.
- Reliance on GE Healthcare for equipment sales.
- Limited brand recognition compared to larger competitors.
Catalysts
- Upcoming: Expansion of the IT segment with new software solutions for diagnostic imaging.
- Ongoing: Increased sales of proprietary medical devices, such as Holter monitors and wireless vital-sign monitoring systems.
- Ongoing: Strategic partnerships to expand product offerings and market reach.
- Ongoing: Geographic expansion into new markets.
Risks
- Potential: Competition from larger, more established players in the healthcare IT and medical device markets.
- Potential: Technological obsolescence of medical devices.
- Potential: Regulatory changes impacting healthcare IT and medical devices.
- Ongoing: High debt-to-equity ratio increases financial risk.
- Ongoing: Reliance on GE Healthcare for equipment sales.
Growth Opportunities
- Expansion of IT Segment: Vaso Corporation can expand its IT segment by offering advanced healthcare software solutions and managed network services. The healthcare IT market is projected to reach $390 billion by 2027, driven by the increasing adoption of electronic health records and the need for data security. By investing in innovative IT solutions, Vaso Corporation can attract new clients and increase its market share. Timeline: Ongoing.
- Increased Sales of Proprietary Medical Devices: Vaso Corporation can increase sales of its proprietary medical devices, such as Biox series Holter monitors and MobiCare wireless vital-sign monitoring systems. The market for remote patient monitoring devices is expected to reach $1.9 billion by 2028, driven by the growing prevalence of chronic diseases and the increasing demand for home healthcare. By focusing on product innovation and marketing, Vaso Corporation can capture a larger share of this market. Timeline: Ongoing.
- Strategic Partnerships: Vaso Corporation can form strategic partnerships with other healthcare companies to expand its product offerings and reach new markets. By partnering with companies that offer complementary products and services, Vaso Corporation can create a more comprehensive solution for its clients. Timeline: Ongoing.
- Geographic Expansion: Vaso Corporation can expand its geographic presence by targeting new markets in the United States and internationally. The global healthcare market is growing rapidly, driven by the increasing demand for healthcare services in developing countries. By establishing a presence in new markets, Vaso Corporation can diversify its revenue streams and reduce its reliance on the U.S. market. Timeline: Ongoing.
- Enhanced External Counterpulsation (EECP) Therapy Systems: With the increasing prevalence of ischemic heart disease, Vaso Corporation can focus on expanding the reach of its EECP therapy systems. As a non-invasive outpatient treatment, EECP presents a compelling alternative to more invasive procedures, aligning with the growing preference for less intrusive medical interventions. By increasing awareness and adoption of EECP, Vaso Corporation can tap into a significant market opportunity. Timeline: Ongoing.
Opportunities
- Expansion of IT segment through innovative solutions.
- Increased sales of proprietary medical devices in remote patient monitoring.
- Strategic partnerships to expand product offerings and market reach.
- Geographic expansion into new markets.
Threats
- Competition from larger, more established players.
- Technological obsolescence of medical devices.
- Regulatory changes impacting healthcare IT and medical devices.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Established relationships with GE Healthcare.
- Proprietary medical device technology.
- Recurring revenue from IT service contracts.
- Specialized expertise in healthcare IT and medical devices.
About VASO
Vaso Corporation, originally incorporated as Vasomedical, Inc. in 1987 and renamed in 2016, operates within the healthcare equipment and information technology sectors. The company is structured into three primary segments: IT, Professional Sales Service, and Equipment. The IT segment delivers managed healthcare software solutions, encompassing diagnostic imaging applications, network infrastructure management, network transport, and security services. This segment is crucial for healthcare providers seeking to optimize their IT infrastructure and ensure data security. The Professional Sales Service segment focuses on facilitating the sale of healthcare capital equipment from General Electric Healthcare (GEHC) to health providers, particularly targeting the middle market. This includes GEHC diagnostic imaging equipment, ultrasound systems, service agreements, training, and financial services, providing a comprehensive suite of solutions for healthcare facilities looking to upgrade or expand their equipment base. The Equipment segment is dedicated to the design, manufacture, and service of proprietary medical devices and software. Products include the Biox series Holter monitors and ambulatory blood pressure recorders, ARCS series analysis software for ECG and blood pressure signals, MobiCare multi-parameter wireless vital-sign monitoring systems, and Enhanced External Counterpulsation (EECP) therapy systems for treating ischemic heart disease. These devices cater to the growing need for non-invasive and outpatient treatment options. Based in Plainview, New York, Vaso Corporation serves a diverse range of healthcare providers in the United States and internationally.
What They Do
- Provides healthcare IT solutions, including diagnostic imaging applications.
- Offers managed network infrastructure, transport, and security services.
- Sells healthcare capital equipment for General Electric Healthcare (GEHC).
- Offers GEHC diagnostic imaging equipment and ultrasound systems.
- Manufactures and services proprietary medical devices and software.
- Produces Biox series Holter monitors and ambulatory blood pressure recorders.
- Develops ARCS series analysis software for ECG and blood pressure signals.
- Offers MobiCare multi-parameter wireless vital-sign monitoring systems.
Business Model
- Generates revenue through the sale of healthcare IT solutions and services.
- Earns commissions from the sale of GEHC healthcare capital equipment.
- Derives revenue from the sale and service of proprietary medical devices.
- Offers software subscriptions and algorithm services for ECG and blood pressure analysis.
Industry Context
Vaso Corporation operates in the health information services industry, which is experiencing growth due to the increasing adoption of healthcare IT solutions and the rising demand for remote patient monitoring. The industry is characterized by technological advancements, regulatory changes, and competitive pressures. Vaso Corporation's focus on healthcare IT, medical devices, and professional sales services positions it to capitalize on these trends. However, it faces competition from larger, more established players in the market.
Key Customers
- Hospitals and healthcare systems
- Diagnostic imaging centers
- Physician practices
- Outpatient clinics
Financials
Chart & Info
Vaso Corporation (VASO) stock price: Price data unavailable
Latest News
No recent news available for VASO.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VASO.
Price Targets
Wall Street price target analysis for VASO.
MoonshotScore
What does this score mean?
The MoonshotScore rates VASO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Health Information ServicesCompetitors & Peers
VASO OTC Market Information
VASO trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
Vaso Corporation Stock: Key Questions Answered
What does Vaso Corporation do?
Vaso Corporation operates in the healthcare equipment and information technology sectors, providing a range of products and services through its three segments: IT, Professional Sales Service, and Equipment. The IT segment offers healthcare software solutions and managed network services. The Professional Sales Service segment facilitates the sale of GE Healthcare equipment. The Equipment segment designs, manufactures, and services proprietary medical devices like Holter monitors and EECP therapy systems. The company serves healthcare providers in the United States and internationally.
What do analysts say about VASO stock?
As of 2026-03-18, formal analyst ratings for Vaso Corporation (VASO) are not widely available, likely due to its small market capitalization. Investors generally consider the company's financial metrics, such as its gross margin of 60.9% and ROE of 9.6%, alongside its growth opportunities in healthcare IT and medical devices. However, the high debt-to-equity ratio and reliance on GEHC are also key considerations. Investors should conduct their own due diligence.
What are the main risks for VASO?
Vaso Corporation faces several risks, including intense competition in the healthcare IT and medical device markets from larger, more established companies. Technological obsolescence poses a threat to its medical device offerings. Regulatory changes in the healthcare industry could impact its IT and equipment segments. The company's high debt-to-equity ratio increases financial risk, and its reliance on GE Healthcare for equipment sales exposes it to potential disruptions in that relationship.
What are the key factors to evaluate for VASO?
Vaso Corporation (VASO) currently holds an AI score of 49/100, indicating low score. Key strength: Diverse product and service offerings across IT, sales, and equipment segments.. Primary risk to monitor: Potential: Competition from larger, more established players in the healthcare IT and medical device markets.. This is not financial advice.
How frequently does VASO data refresh on this page?
VASO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven VASO's recent stock price performance?
Recent price movement in Vaso Corporation (VASO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse product and service offerings across IT, sales, and equipment segments.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider VASO overvalued or undervalued right now?
Determining whether Vaso Corporation (VASO) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying VASO?
Before investing in Vaso Corporation (VASO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- The analysis is based on publicly available information and may be subject to change.